BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Oral belinostat: Phase I/II started

TopoTarget said investigators began an open-label, Danish Phase I/II trial to evaluate daily oral belinostat given the first 2 weeks of a 3-week cycle plus Tarceva erlotinib in 35 previously treated NSCLC...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >